Future collaborative multicenter studies will hopefully allow for analyses of more extensive patient cohorts also in these rare disorders to unequivocally determine the significance of anti-PF4/heparin antibodies for thrombotic risk in MPN. This evidence concerns the gene PF4 and myeloproliferative disorder.